![Bogdan Dziurzynski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bogdan Dziurzynski
Plus aucun poste en cours
Historique de carrière de Bogdan Dziurzynski
Anciens postes connus de Bogdan Dziurzynski
Sociétés | Poste | Début | Fin |
---|---|---|---|
DENDREON CORPORATION | Directeur/Membre du Conseil | 01/05/2001 | 23/02/2015 |
Independent Dir/Board Member | 01/05/2001 | 23/02/2015 | |
ANTHERA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 05/03/2012 | 10/06/2014 |
Independent Dir/Board Member | 05/03/2012 | 10/06/2014 | |
MedImmune LLC
![]() MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Conseiller Juridique Général | 01/01/1994 | 01/01/2001 |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Conseiller Juridique Général | 01/01/1988 | 01/01/1994 |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
C.R. BARD | Corporate Officer/Principal | - | - |
Genetic Systems Corp. | Corporate Officer/Principal | 20/04/2010 | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Directeur/Membre du Conseil | 01/01/2009 | - |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Président | - | - |
░░░░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de Bogdan Dziurzynski
Rutgers State University of New Jersey | Undergraduate Degree |
Seattle University | Masters Business Admin |
University of Southern California | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 12 |
France | 2 |
Canada | 2 |
Opérationnelle
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Independent Dir/Board Member | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 4 |
Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
ANTHERA PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 8 |
---|---|
Dendreon Corp.
![]() Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Biologics Consulting Group, Inc.
![]() Biologics Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Biologics Consulting Group, Inc. provides regulatory and product development advisory services for drugs and device products. It specializes in the preparation and review of CBER, CDER and CDRH regulatory applications, facility inspection, process validation packages, and electronic submissions. The company was founded by James G. Kenimer in 1993 and is headquartered in Alexandria, VA. | Commercial Services |
Regulatory Affairs Professionals Society
![]() Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Commercial Services |
MedImmune LLC
![]() MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Genetic Systems Corp. | |
C. R. Bard, Inc. (New Jersey)
![]() C. R. Bard, Inc. (New Jersey) Medical SpecialtiesHealth Technology C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ. | Health Technology |
- Bourse
- Insiders
- Bogdan Dziurzynski
- Expérience